Oncology Drugs Industry Research Report 2025

Summary

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

According to APO Research, The global Oncology Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Oncology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Oncology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Oncology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Oncology Drugs include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.
The Oncology Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Oncology Drugs Segment by Company

Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Oncology Drugs Segment by Type

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Oncology Drugs Segment by Application

Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
Oncology Drugs Segment by Application

Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
Oncology Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncology Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Oncology Drugs by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Chemotherapy
2.2.3 Targeted Therapy
2.2.4 Immunotherapy (Biologic Therapy)
2.2.5 Hormonal Therapy
2.2.6 Others
2.3 Oncology Drugs by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Blood Cancer
2.3.3 Breast Cancer
2.3.4 Gastrointestinal Cancer
2.3.5 Prostate Cancer
2.3.6 Respiratory or Lung Cancer
2.3.7 Others
2.4 Assumptions and Limitations
3 Oncology Drugs Breakdown Data by Type
3.1 Global Oncology Drugs Historic Market Size by Type (2020-2025)
3.2 Global Oncology Drugs Forecasted Market Size by Type (2026-2031)
4 Oncology Drugs Breakdown Data by Application
4.1 Global Oncology Drugs Historic Market Size by Application (2020-2025)
4.2 Global Oncology Drugs Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Oncology Drugs Market Perspective (2020-2031)
5.2 Global Oncology Drugs Growth Trends by Region
5.2.1 Global Oncology Drugs Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Oncology Drugs Historic Market Size by Region (2020-2025)
5.2.3 Oncology Drugs Forecasted Market Size by Region (2026-2031)
5.3 Oncology Drugs Market Dynamics
5.3.1 Oncology Drugs Industry Trends
5.3.2 Oncology Drugs Market Drivers
5.3.3 Oncology Drugs Market Challenges
5.3.4 Oncology Drugs Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Oncology Drugs Players by Revenue
6.1.1 Global Top Oncology Drugs Players by Revenue (2020-2025)
6.1.2 Global Oncology Drugs Revenue Market Share by Players (2020-2025)
6.2 Global Oncology Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Oncology Drugs Head Office and Area Served
6.4 Global Oncology Drugs Players, Product Type & Application
6.5 Global Oncology Drugs Manufacturers Established Date
6.6 Global Oncology Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Oncology Drugs Market Size (2020-2031)
7.2 North America Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Oncology Drugs Market Size by Country (2020-2025)
7.4 North America Oncology Drugs Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Oncology Drugs Market Size (2020-2031)
8.2 Europe Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Oncology Drugs Market Size by Country (2020-2025)
8.4 Europe Oncology Drugs Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Oncology Drugs Market Size (2020-2031)
9.2 Asia-Pacific Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Oncology Drugs Market Size by Country (2020-2025)
9.4 Asia-Pacific Oncology Drugs Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Oncology Drugs Market Size (2020-2031)
10.2 South America Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Oncology Drugs Market Size by Country (2020-2025)
10.4 South America Oncology Drugs Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Oncology Drugs Market Size (2020-2031)
11.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Oncology Drugs Market Size by Country (2020-2025)
11.4 Middle East & Africa Oncology Drugs Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Roche
12.1.1 Roche Company Information
12.1.2 Roche Business Overview
12.1.3 Roche Revenue in Oncology Drugs Business (2020-2025)
12.1.4 Roche Oncology Drugs Product Portfolio
12.1.5 Roche Recent Developments
12.2 Celgene
12.2.1 Celgene Company Information
12.2.2 Celgene Business Overview
12.2.3 Celgene Revenue in Oncology Drugs Business (2020-2025)
12.2.4 Celgene Oncology Drugs Product Portfolio
12.2.5 Celgene Recent Developments
12.3 Novartis
12.3.1 Novartis Company Information
12.3.2 Novartis Business Overview
12.3.3 Novartis Revenue in Oncology Drugs Business (2020-2025)
12.3.4 Novartis Oncology Drugs Product Portfolio
12.3.5 Novartis Recent Developments
12.4 Bristol-Myers Squibb
12.4.1 Bristol-Myers Squibb Company Information
12.4.2 Bristol-Myers Squibb Business Overview
12.4.3 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2020-2025)
12.4.4 Bristol-Myers Squibb Oncology Drugs Product Portfolio
12.4.5 Bristol-Myers Squibb Recent Developments
12.5 Johnson & Johnson
12.5.1 Johnson & Johnson Company Information
12.5.2 Johnson & Johnson Business Overview
12.5.3 Johnson & Johnson Revenue in Oncology Drugs Business (2020-2025)
12.5.4 Johnson & Johnson Oncology Drugs Product Portfolio
12.5.5 Johnson & Johnson Recent Developments
12.6 Merck & Co.
12.6.1 Merck & Co. Company Information
12.6.2 Merck & Co. Business Overview
12.6.3 Merck & Co. Revenue in Oncology Drugs Business (2020-2025)
12.6.4 Merck & Co. Oncology Drugs Product Portfolio
12.6.5 Merck & Co. Recent Developments
12.7 AstraZeneca
12.7.1 AstraZeneca Company Information
12.7.2 AstraZeneca Business Overview
12.7.3 AstraZeneca Revenue in Oncology Drugs Business (2020-2025)
12.7.4 AstraZeneca Oncology Drugs Product Portfolio
12.7.5 AstraZeneca Recent Developments
12.8 Pfizer
12.8.1 Pfizer Company Information
12.8.2 Pfizer Business Overview
12.8.3 Pfizer Revenue in Oncology Drugs Business (2020-2025)
12.8.4 Pfizer Oncology Drugs Product Portfolio
12.8.5 Pfizer Recent Developments
12.9 Amgen
12.9.1 Amgen Company Information
12.9.2 Amgen Business Overview
12.9.3 Amgen Revenue in Oncology Drugs Business (2020-2025)
12.9.4 Amgen Oncology Drugs Product Portfolio
12.9.5 Amgen Recent Developments
12.10 Eli Lilly
12.10.1 Eli Lilly Company Information
12.10.2 Eli Lilly Business Overview
12.10.3 Eli Lilly Revenue in Oncology Drugs Business (2020-2025)
12.10.4 Eli Lilly Oncology Drugs Product Portfolio
12.10.5 Eli Lilly Recent Developments
12.11 AbbVie
12.11.1 AbbVie Company Information
12.11.2 AbbVie Business Overview
12.11.3 AbbVie Revenue in Oncology Drugs Business (2020-2025)
12.11.4 AbbVie Oncology Drugs Product Portfolio
12.11.5 AbbVie Recent Developments
12.12 Takeda
12.12.1 Takeda Company Information
12.12.2 Takeda Business Overview
12.12.3 Takeda Revenue in Oncology Drugs Business (2020-2025)
12.12.4 Takeda Oncology Drugs Product Portfolio
12.12.5 Takeda Recent Developments
12.13 Astellas
12.13.1 Astellas Company Information
12.13.2 Astellas Business Overview
12.13.3 Astellas Revenue in Oncology Drugs Business (2020-2025)
12.13.4 Astellas Oncology Drugs Product Portfolio
12.13.5 Astellas Recent Developments
12.14 Ipsen
12.14.1 Ipsen Company Information
12.14.2 Ipsen Business Overview
12.14.3 Ipsen Revenue in Oncology Drugs Business (2020-2025)
12.14.4 Ipsen Oncology Drugs Product Portfolio
12.14.5 Ipsen Recent Developments
12.15 Sanofi
12.15.1 Sanofi Company Information
12.15.2 Sanofi Business Overview
12.15.3 Sanofi Revenue in Oncology Drugs Business (2020-2025)
12.15.4 Sanofi Oncology Drugs Product Portfolio
12.15.5 Sanofi Recent Developments
12.16 Bayer
12.16.1 Bayer Company Information
12.16.2 Bayer Business Overview
12.16.3 Bayer Revenue in Oncology Drugs Business (2020-2025)
12.16.4 Bayer Oncology Drugs Product Portfolio
12.16.5 Bayer Recent Developments
12.17 Biogen Idec
12.17.1 Biogen Idec Company Information
12.17.2 Biogen Idec Business Overview
12.17.3 Biogen Idec Revenue in Oncology Drugs Business (2020-2025)
12.17.4 Biogen Idec Oncology Drugs Product Portfolio
12.17.5 Biogen Idec Recent Developments
12.18 Teva
12.18.1 Teva Company Information
12.18.2 Teva Business Overview
12.18.3 Teva Revenue in Oncology Drugs Business (2020-2025)
12.18.4 Teva Oncology Drugs Product Portfolio
12.18.5 Teva Recent Developments
12.19 Otsuka
12.19.1 Otsuka Company Information
12.19.2 Otsuka Business Overview
12.19.3 Otsuka Revenue in Oncology Drugs Business (2020-2025)
12.19.4 Otsuka Oncology Drugs Product Portfolio
12.19.5 Otsuka Recent Developments
12.20 Eisai
12.20.1 Eisai Company Information
12.20.2 Eisai Business Overview
12.20.3 Eisai Revenue in Oncology Drugs Business (2020-2025)
12.20.4 Eisai Oncology Drugs Product Portfolio
12.20.5 Eisai Recent Developments
12.21 Merck KGaA
12.21.1 Merck KGaA Company Information
12.21.2 Merck KGaA Business Overview
12.21.3 Merck KGaA Revenue in Oncology Drugs Business (2020-2025)
12.21.4 Merck KGaA Oncology Drugs Product Portfolio
12.21.5 Merck KGaA Recent Developments
12.22 Gilead Sciences
12.22.1 Gilead Sciences Company Information
12.22.2 Gilead Sciences Business Overview
12.22.3 Gilead Sciences Revenue in Oncology Drugs Business (2020-2025)
12.22.4 Gilead Sciences Oncology Drugs Product Portfolio
12.22.5 Gilead Sciences Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings